Do Clinical Grant Payment Practices in Phase 3 Clinical Trials Influence Subsequent Clinical Investigator Prescribing Behavior?

Disease Management

Volumn 7, Issue 1, 2004, Pages 77-87

  Glass, Harold E ^a  

^a TTC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BEHAVIOR; CALCULATION; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; CONSULTATION; CORRELATION ANALYSIS; DOCTOR PATIENT RELATION; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SCREENING; FEMALE; FINANCIAL MANAGEMENT; HEALTH CARE COST; HUMAN; LINEAR REGRESSION ANALYSIS; MALE; MARKET; NORMAL HUMAN; OUTPATIENT DEPARTMENT; PHASE 3 CLINICAL TRIAL; PHYSICIAN; PRESCRIPTION; STATISTICAL SIGNIFICANCE; TREATMENT INDICATION; UNITED STATES; WORK;

ADULT; AGED; AGED, 80 AND OVER; CLINICAL TRIALS, PHASE III; FEMALE; HEALTH SERVICES RESEARCH; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; TRAINING SUPPORT;

EID: 1842422187     PISSN: 1093507X     EISSN: None     Source Type: Journal    
DOI: 10.1089/109350704322919014     Document Type: Article

References (17)

1. Orlowski JP, Wateska P. The effects of pharmaceutical firm enticements on physician prescribing patterns. There's no such thing as a free lunch. Chest 1992;102:270-273.
2. Lexchin J. Interactions between physicians and the pharmaceutical industry: what does the literature say? Can Med Assoc J 1993;149:1401-1407.
3. Komesaroff PA, Kerridge IH. Ethical issues concerning the relationship between medical practitioners and the pharmaceutical industry. Med J Aust 2002; 176(3):18-21.
4. Miller FG, Schorr AF. Ethical assessment of industry-sponsored trials. Chest 2002;121:1337-1342.
5. Vento S. How tainted is medicine? Lancet 2002;359: 1775-1776.
6. Kaiser Family Foundation. National Survey of Physicians Part II: Doctors and prescription drugs. Menlo Park, CA: Kaiser Family Foundation, 2002.
7. Zisson S. The investigator-prescriber effect comes to light. Centerwatch 2002;9:1-8.
8. Morin K, Rakatansky H, Riddick FA Jr, et al. Managing conflicts of interest in the conduct of clinical trials. JAMA 2002;287:78-84.
9. Bradley CP, Greenfield SM, Jones MI, et al. Proton pump inhibitors: a study of GP's prescribing. Fam Pract 2001;18:333-338.
10. Avorn J, Chen M, Hartley R. Scientific versus commercial sources on the prescribing behavior of physicians. Am J Med 1982;73:4-8.
11. Guldal D, Semin S. The influences of drug companies' advertising programs on physicians. Int J Health Serv 2000;30:5085-5095.
12. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 2000;283: 373-380.
13. PhRMA adopts new marketing code [press release]. Washington, DC: Executive Committee of the Pharmaceutical Research and Manufacturers of America; April 19, 2002.
14. Glass HE. Higher payments to investigators don't speed study completion. Appl Clin Trials 1995;4:40.
15. Xponent®[database]. Plymouth Meeting, PA: IMS Health, Inc., 1999-2000.
16. Hovde M, Seskin R. Selecting U.S. clinical investigators. Appl Clin Trials 1997;6:34-42.
17. Glass HE, Kane RA. Why investigators take part in clinical trials. Appl Clin Trials 2000;9:46-54.